VERICEL CORPORATION Acquisitions, Net of Cash Acquired
VERICEL CORPORATION (VCEL) reported Acquisitions, Net of Cash Acquired of $46.30 million for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-05.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired · last filed 2019-11-05
- VERICEL CORPORATION payments to acquire businesses, net of cash acquired for the quarter ending 2019-09-30 was $13.90M, a 68.75% decline year-over-year.
- VERICEL CORPORATION payments to acquire businesses, net of cash acquired for the quarter ending 2019-06-30 was $21.72M.
- VERICEL CORPORATION payments to acquire businesses, net of cash acquired for the quarter ending 2019-03-31 was $10.69M.
- VERICEL CORPORATION payments to acquire businesses, net of cash acquired for the quarter ending 2018-09-30 was $44.48M.
- VERICEL CORPORATION payments to acquire businesses, net of cash acquired for fiscal 2016 was $0.00.
- VERICEL CORPORATION payments to acquire businesses, net of cash acquired for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
- VERICEL CORPORATION payments to acquire businesses, net of cash acquired for fiscal 2014 was $1.45M.
- VERICEL CORPORATION payments to acquire businesses, net of cash acquired for fiscal 2013 was $0.00.
| Period end | Payments to Acquire Businesses, Net of Cash Acquired 3 month | Payments to Acquire Businesses, Net of Cash Acquired 3 month as first filed | Payments to Acquire Businesses, Net of Cash Acquired 6 month | Payments to Acquire Businesses, Net of Cash Acquired 6 month as first filed | Payments to Acquire Businesses, Net of Cash Acquired 9 month | Payments to Acquire Businesses, Net of Cash Acquired 9 month as first filed | Payments to Acquire Businesses, Net of Cash Acquired 12 month |
|---|---|---|---|---|---|---|---|
| 2019-09-30 | $13.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $35.62M derived: sum of 2 quarters · filed 2019-11-05 | $46.30M 10-Q · filed 2019-11-05 | ||||
| 2019-06-30 | $21.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $32.40M 10-Q · filed 2019-08-06 | |||||
| 2019-03-31 | $10.69M 10-Q · filed 2019-05-07 | ||||||
| 2018-09-30 | $44.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $44.48M derived: sum of 2 quarters · filed 2019-11-05 | $44.48M 10-Q · filed 2019-11-05 | ||||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $0.00 10-Q · filed 2019-08-06 | $979.00K 10-Q · filed 2018-08-06 | ||||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-07 | $184.00K 10-Q · filed 2018-05-08 | |||||
| 2017-09-30 | -$273.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$70.00K derived: sum of 2 quarters · filed 2018-11-06 | $0.00 10-Q · filed 2018-11-06 | $792.00K 10-Q · filed 2017-11-07 | -$1.31M derived: sum of 4 quarters · filed 2018-11-06 | ||
| 2017-06-30 | $203.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $273.00K 10-Q · filed 2018-08-06 | -$1.04M derived: sum of 3 quarters · filed 2018-08-06 | -$801.00K derived: sum of 4 quarters · filed 2018-08-06 | |||
| 2017-03-31 | $70.00K 10-Q · filed 2018-05-08 | -$1.24M derived: sum of 2 quarters · filed 2018-05-08 | -$1.00M derived: sum of 3 quarters · filed 2018-05-08 | $57.00K derived: sum of 4 quarters · filed 2018-05-08 | |||
| 2016-12-31 | -$1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13 | -$1.07M derived: sum of 2 quarters · filed 2017-11-07 | -$13.00K derived: sum of 3 quarters · filed 2017-11-07 | $0.00 10-K · filed 2017-03-13 | |||
| 2016-09-30 | $240.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $1.30M derived: sum of 2 quarters · filed 2017-11-07 | $1.31M 10-Q · filed 2017-11-07 | -$1.02M derived: sum of 4 quarters · filed 2017-11-07 | |||
| 2016-06-30 | $1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $1.07M 10-Q · filed 2017-08-09 | -$1.26M derived: sum of 3 quarters · filed 2017-08-09 | -$481.00K derived: sum of 4 quarters · filed 2017-08-09 | |||
| 2016-03-31 | $13.00K 10-Q · filed 2017-05-10 | -$2.32M derived: sum of 2 quarters · filed 2017-05-10 | -$1.54M derived: sum of 3 quarters · filed 2017-05-10 | -$340.00K derived: sum of 4 quarters · filed 2017-05-10 | |||
| 2015-12-31 | -$2.33M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13 | -$1.55M derived: sum of 2 quarters · filed 2017-03-13 | -$353.00K derived: sum of 3 quarters · filed 2017-03-13 | $0.00 10-K · filed 2017-03-13 | |||
| 2015-09-30 | $775.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $1.98M derived: sum of 2 quarters · filed 2016-11-07 | $2.33M 10-Q · filed 2016-11-07 | $0.00 10-Q · filed 2015-11-13 | $2.33M derived: sum of 4 quarters · filed 2017-03-13 | ||
| 2015-06-30 | $1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $1.55M 10-Q · filed 2016-08-08 | $0.00 10-Q · filed 2015-08-12 | $1.55M derived: sum of 3 quarters · filed 2017-03-13 | $4.05M derived: sum of 4 quarters · filed 2017-03-13 | ||
| 2015-03-31 | $353.00K 10-Q · filed 2016-05-10 | $353.00K derived: sum of 2 quarters · filed 2017-03-13 | $2.85M derived: sum of 3 quarters · filed 2017-03-13 | $1.80M derived: sum of 4 quarters · filed 2017-03-13 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13 | $2.50M derived: sum of 2 quarters · filed 2017-03-13 | $1.45M derived: sum of 3 quarters · filed 2017-03-13 | $1.45M 10-K · filed 2017-03-13 | |||
| 2014-09-30 | $2.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $1.45M derived: sum of 2 quarters · filed 2015-11-13 | $1.45M 10-Q · filed 2015-11-13 | ||||
| 2014-06-30 | -$1.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-12 | -$1.05M 10-Q · filed 2015-08-12 | |||||
| 2014-03-31 | $0.00 10-Q · filed 2015-05-14 | ||||||
| 2013-12-31 | $0.00 10-K · filed 2016-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |